"Good Morning America" co-host Robin Roberts, who five years ago beat breast cancer, said Monday that she has now been diagnosed with myelodysplastic syndrome, a blood disorder caused by chemotherapy for her cancer. She is now taking chemotherapy in preparation for receiving a bone marrow transplant from her sister later this year. Because she is relatively young and healthy, the combination of treatments should cure the condition, doctors have told her.

Myelodysplastic syndrome is sometimes known as pre-leukemia, and many researchers now believe that, if untreated, it will progress to acute myeloid leukemia. It most commonly strikes people between the ages of 58 and 75, but can occur at any age, particularly if the patient has had cancer chemotherapy. It is estimated to affect as many as 50 Americans per 100,000, with about 20,000 new cases each year.

It is a disease of the bone marrow -- the semi-liquid tissue inside bones that produces blood cells. Stem cells in the bone marrow develop into two types of cells, myeloid and lymphoid. Lymphoid cells go on to become white blood cells that fight infections. Myeloid cells develop into three different types of cells: red blood cells, which carry oxygen; platelets, which control bleeding by forming clots; and white blood cells. In myeloplastic syndrome the myeloid cells stop developing; they do not function normally and either die in the bone marrow or soon after they enter the blood. The dysfunctional cells crowd out healthy cells.

Symptoms are often not apparent, but can include shortness of breath, weakness or tiredness, pale skin, easy bruising and bleeding, and fever or frequent infections. The best treatment for the type of disorder Roberts is suffering is to kill all the stem cells with chemotherapy, then replace them with functioning stem cells from a donor -- in this case, her sister. Treatment is usually more effective when the disorder has been caused by chemotherapy.

Roberts announced her condition on the show and on the ABC blog, saying she will continue her job at "Good Morning America" and that "My doctors tell me Im going to beat this and I know its true."

LATimesScience@gmail.com

Twitter/@LATMaugh

See more here:
'Good Morning America' co-host Robin Roberts has blood disorder

061112_RobinRobertsABC_ftrGood Morning America host Robin Roberts announced June 11 that she was diagnosed with Myelodysplastic Syndrome (MDS), a blood disorder affecting the stem cells in the bone marrow. Celebrities and first lady Michelle Obama have already offered their support on Twitter!

Robin Robertshas a special connection to The Obamas: She found out she was interviewingPresident Obama on the very same day she underwent a painful bone marrow extraction. The combination of landing the biggest interview of my career and having a drill in my back reminds me that God only gives us what we can handle and that it helps to have a good sense of humor when we run smack into the absurdity of life, Robin wrote on her blog. And First Lady Michelle Obama was quick to offer her condolences to the GMA host.

.@RobinRoberts, Barack and I have you in our prayers. We believe in you and thank you for bringing awareness and hope to others. mo, Michelletweeted June 11.

Heres what other celebs tweeted about Robin:

prayers for Robin Roberts tweeted hip-hop mogul Russell Simmons.

We all love you & are cheering you on!! tweeted fellow journalist Katie Couric.

I wish my friend@RobinRobertsthe strength, faith & love she will need on this new journey. I send all that and more. tweeted Maria Shriver.

More on Robin Roberts:

Get more from Hollywoodlife.com: Follow us on Twitter, Facebook, Newsletter

See original here:
Michelle Obama & More Celebs Tweet At Robin Roberts After MDS Diagnosis

Good Morning America host Robin Roberts announced on Monday June 11 that she was diagnosed with Myelodysplastic Syndrome (MDS), a blood disorder affecting the stem cells in the bone marrow. Find out all the details on the disease!

Robin Roberts bravely announced to the world on Monday June 11 that she has been diagnosed with Myelodysplastic Syndrome, formerly known as preleukemia. The GMA host held back tears as she held her co-hosts hands and revealed her painful secret that shes held for more than a month. MDS is a blood-related condition that involves ineffective production of the myeloid class of blood cells.It is a rare blood disorder that affects the bone marrow, she said.

Left without a transplant, the disease worsens and the patient develops low blood counts due to progressive bone marrow failure. Found mostly in patients between 60 and 75, Robin was diagnosed at the age of 51-years-old leaving her with a good prognosis.

Symptoms can involve severe anemia and require frequent blood transfusions. The mean life-expectancy is 18 to 24 months in mild cases of MDS or even longer when stem cell transplantation is done, but all cases vary.

Robin, who has experienced a series of highs and lows throughout her career, announced that her sister, Sally-Ann Roberts, would be her donor! I am blessed, Robin said because her sister is a virtually perfect bone marrow match. Thankfully,Robins doctors are optimistic of her recovery!My doctors tell me Im going to beat this and I know its true, Robin said.

Success of bone marrow transplantation has been found to correlate with severity of MDS.

Famous patients with MDS include astronomerCarl SaganandwriterRoald Dahl(James and the Giant Peach,Charlie and the Chocolate Factory,) and more.

We wish Robin the best and will be rooting for her throughout her treatments!

HollywoodLifers, do you know someone with MDS? Tell us your story below!

The rest is here:
Robin Roberts Diagnosed With MDS — Details on Her Disease

ScienceDaily (June 11, 2012) Studying mice and humans, researchers at Washington University School of Medicine in St. Louis and their collaborators in Paris have identified two proteins that are required to maintain a supply of stem cells in the developing kidney.

In the presence of the two proteins, FGF9 and FGF20, mouse kidney stem cells stayed alive outside the body longer than previously reported. Though the cells were maintained only five days (up from about two), the work is a small step toward the future goal of growing kidney stem cells in the lab.

In the developing embryo, these early stem cells give rise to adult cells called nephrons, the blood filtration units of the kidneys.

The results appear online June 11 in Developmental Cell.

"When we are born, we get a certain allotment of nephrons," says Raphael Kopan, PhD, the Alan A. and Edith L. Wolff Professor of Developmental Biology. "Fortunately, we have a large surplus. We can donate a kidney -- give away 50 percent of our nephrons -- and still do fine. But, unlike our skin and gut, our kidneys can't build new nephrons."

The skin and the gut have small pools of stem cells that continually renew these organs throughout life. Scientists call such pools of stem cells and their support system a niche. During early development, the embryonic kidney has a stem cell niche as well. But at some point before birth or shortly after, all stem cells in the kidney differentiate to form nephrons, leaving no self-renewing pool of stem cells.

"In other organs, there are cells that specifically form the niche, supporting the stem cells in a protected environment," Kopan says. "But in the embryonic kidney, it seems the stem cells form their own niche, making it a bit more fragile. And the signals and conditions that lead the cells to form this niche have been elusive."

Surprisingly, recent clues to the signals that maintain the embryonic kidney's stem cell niche came from studies of the inner ear. David M. Ornitz, MD, PhD, the Alumni Endowed Professor of Developmental Biology, investigates FGF signaling in mice. Earlier this year, Ornitz and his colleagues published a paper in PLoS Biology showing that FGF20 plays an important role in inner ear development.

"Mice without FGF20 are profoundly deaf," Ornitz says. "While they are otherwise viable and healthy, in some cases we noticed that their kidneys looked small."

Past work from his own lab and others suggested that FGF9, a close chemical cousin of FGF20, might also participate in kidney development. FGF20 and FGF9 are members of a family of proteins known as fibroblast growth factors. In general, members of this family are known to play important and broad roles in embryonic development, tissue maintenance, and wound healing. Mice lacking FGF9 have defects in development of the male urogenital tract and die after birth due to defects in lung development.

Continue reading here:
Clues found to way embryonic kidney maintains its fleeting stem cells

SAN DIEGO , June 11, 2012 /CNW/ - Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies. BD SMC4 is a patent protected, pre-formulated cocktail of small molecules for improving cellular reprogramming efficiencies and for enabling single-cell passaging and flow cytometry sorting of iPSCs in feeder cell-free and other pluripotent cell culture systems.

"iPSCs have the potential to redefine the way medical research is conducted," said Dr. Charles Crespi , Vice President at BD Biosciences. "However, most current reprogramming technologies are inefficient, which slows research efforts. BD SMC4 is an exciting complement to the BD portfolio of stem cell technologies that can accelerate the pace of research, and, ultimately, drug development."

The collaboration between BD Biosciences and Fate Therapeutics seeks to provide life science researchers and the pharmaceutical community reliable access to advanced iPSC tools and technologies. These technologies are for use in human disease research, drug discovery and the manufacture of cell-based therapies. The identification of the small molecule additives, and their use in an industrial platform for iPSC generation and characterization was recently published in the journal, Scientific Reports (Valamehr et al Scientific Reports 2, Article number: 213, 2012).

"Our research focus has uncovered novel technologies to enable the commercial and industrial application of iPS cells," said Dr. Peter Flynn , Vice President of Biologic Therapeutics at Fate Therapeutics. "The BD SMC4 media additive was developed at Fate to enable our scientists to internally perform high-throughput generation, clonal selection, characterization and expansion of pluripotent cells, and we are excited to empower the stem cell research community with these important iPSC technologies through our collaboration with BD."

iPSC technology holds great promise for disease modeling, drug screening and toxicology testing as well as for autologous and allogeneic cell therapy. Building on the foundational work of its scientific founders, Drs. Rudolf Jaenisch and Sheng Ding, Fate Therapeutics is developing a suite of proprietary products and technologies to overcome the remaining technical hurdles for iPS cell integration into the therapeutic development process. Under the three-year collaboration, Fate and BD will co-develop certain stem cell products using Fate's award-winning iPSC technology platform, and BD will commercialize these stem cell products on a worldwide basis. The iPSC product platform of Fate Therapeutics is supported by foundational intellectual property including U.S. Patent No. 8,071,369, entitled "Compositions for Reprogramming Somatic Cells," which claims a composition comprising a somatic cell having an exogenous nucleic acid that encodes an Oct4 protein introduced into the cell.

About Fate Therapeutics, Inc. Fate Therapeutics is an innovative biotechnology company developing novel stem cell modulators (SCMs), biologic or small molecule compounds that guide cell fate, to treat patients with very few therapeutic options. Fate Therapeutics' lead clinical program, ProHema, consists of pharmacologically-enhanced hematopoietic stem cells (HSCs), designed to improve HSC support during the normal course of a stem cell transplant for the treatment of patients with hematologic malignancies. The Company is also advancing a robust pipeline of human recombinant proteins, each with novel mechanisms of action, for skeletal muscle, beta-islet cell, and post-ischemic tissue regeneration. Fate Therapeutics also applies its award-winning, proprietary induced pluripotent stem cell (iPSC) technology to offer a highly efficient platform to recapitulate human physiology for commercial scale drug discovery and therapeutic use. Fate Therapeutics is headquartered in San Diego , CA, with a subsidiary in Ottawa , Canada . For more information, please visit http://www.fatetherapeutics.com.

About BDBD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes , New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.

SOURCE Fate Therapeutics, Inc.

Read the original here:
Fate Therapeutics And BD Biosciences Launch BD™ SMC4 To Improve Cellular Reprogramming And IPS Cell Culture Applications

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/pqrlwc/analysis_of_the_st) has announced the addition of Frost & Sullivan's new report "Analysis of the Stem Cell Markets-Unlocking the New Era in Therapeutics" to their offering.

This Frost & Sullivan research service titled Analysis of the Stem Cell Markets-Unlocking the New Era in Therapeutics focuses on prospects for the stem cell therapeutics market in Europe and provides valuable recommendations and conclusions for market participants. Market segmentation is based on regulatory framework in Europe relating to research on adult and embryonic stem cells. The main countries discussed are the United Kingdom, Germany, France, Spain, Sweden, Finland, and the remaining parts of Europe.

Market Overview

New Applications in Drug Discovery Platforms to Drive Stem Cells Market

Stem cells offer exciting potential in regenerative medicine, and are likely to be widely used by mid-2017. Pharmaceutical, biotech and medical device companies are showing increased interest in stem cell research. The market will be driven by stem cell applications in drug discovery platforms and by successful academia -commercial company partnership models.

The high attrition rates of potential drug candidates has piqued the interest of pharmaceutical and biotech industries in stem cell use during the drug discovery phase, notes the analyst of this research. Previously, animal cell lines, tumours, or genetic transformation have been the traditional platform for testing drug candidates; however, these abnormal' cells have significantly contributed to a lack of translation into clinical studies. Many academic institutes and research centres are collaborating with biotechnology and pharmaceutical companies in stem cell research. This will provide impetus to the emergence of novel cell-based therapies.

Host of Challenges Need to be Confronted before Stem Cell Therapeutics can Realise its Potential

Key challenges to market development relate to reimbursement, ethics and the complexity of clinical trials. Securing reimbursement for stem cell therapeutic products is expected to be critical for commercial success. However, stem cell therapies are likely to be expensive. Insurers, therefore, may be unwilling to pay for the treatment. At the same time, patients are unlikely to be able to afford these treatments. The use of embryonic stem cells raises a host of thorny ethical, legal, and social issues, adds the analyst. As a result, market prices for various products may be affected. Moreover, many research institutes are adopting policies promoting the ethical use of human embryonic tissues. Such policies are hindering the overall research process for several companies working in collaboration with these institutes.

In addition to apprehensions about how many products will actually make it through human-based clinical trials, companies are also worried about which financial model can be applied to stem cell therapies, cautions the analyst. Possibly low return on investment (ROI) is also resulting in pharmaceutical companies adopting a cautious approach to stem cell therapeutics. To push through policy or regulatory reforms, the technology platform and geographical location of stem cell companies should complement the terms laid down in EMEA. The methodology for cell expansion and synchronisation must be optimised to acquire a large population of the desired cell at the right differentiation point, adds the analyst. More research is needed in human pluripotent and multi potent stem cell as it differs from mice to humans. Completion of clinical trials will be essential to ensure the safety and efficacy of the stem cell therapy.

Continue reading here:
Research and Markets: Analysis of the Stem Cell Markets-Unlocking the New Era in Therapeutics

In Early Study, Procedure Helps Teens Halt Insulin Injections

June 11, 2012 (Philadelphia) -- In an early study, an experimental stem cell procedure helped 15 teens with type 1 diabetes stay off of insulin injections for about 1.5 years, on average.

The study was very small, and the procedure is not ready for widespread use. "We now have a unique approach with some positive findings, but it's still early. We need to better understand the biology behind the treatment and follow patients for long-term side effects," Robert E. Ratner, MD, chief scientific and medical officer of the American Diabetes Association, tells WebMD.

This is the latest of several stem cell studies to show promising results for the treatment of type 1 diabetes, Ratner notes.

In the new study, 15 of 28 teens with type 1 diabetes who got an experimental treatment using their own stem cells went into remission and did not need insulin injections for an average of about 1.5 years.

The "cocktail treatment" combines stem cell therapy with drugs that suppress the body's immune system. In type 1 diabetes, the immune system attacks and destroys insulin-producing cells within the pancreas.

The experimental treatment is called autologous nonmyeloablative hematopoietic stem cell transplantation (HSCT). It aims to kill the destructive immune system cells and replace them with immature stem cells not programmed to destroy insulin-producing cells.

First, patients are given drugs to stimulate production of blood stem cells. The blood stem cells are then removed from the body and frozen. Then, patients are hospitalized and given drugs to kill the destructive immune system cells. The harvested blood stem cells are then put back into the patient.

Eight teens who took part in the study have remained insulin-free for two years, on average. One patient has gone without insulin injections for 3.5 years.

"All our patients considered the [treatment] to be worthwhile and beneficial, though some patients experienced side effects," study head Weiqiong Gu, MD, of Ruijin Hospital in Shanghai, tells WebMD.

See original here:
Experimental Stem Cell Treatment Tested for Type 1 Diabetes

A few years ago, concerns over these heart trials were voiced by a Norwegian professor, Harald Arnesen. He concluded in 2007 that they are not convincing and that one German team had achieved striking results only because the control group in its trial had done particularly badly. Prof Arnesen called for a moratorium on this kind of stem-cell therapy.

That still did not deter the clinicians. This January, another trial funded by the EU was announced the largest of all, with 3,000 heart-attack patients recruited from across Europe.

The idea behind the trials is straightforward. During a heart attack, a clogged blood vessel starves heart muscle of oxygen. Up to a billion heart muscle cells, called cardiomyocytes, can be damaged, and the body responds by replacing them with relatively inflexible scar tissue, which can lead to fatal heart failure. So why not implant stem cells that can grow into cardiomyocytes?

Stem cells, of course, come in many kinds: the embryonic variety have the potential to turn into all 200 cell types in the body. Adult stem cells, harvested from the patient, have a more limited repertoire: bone marrow stem cells generate blood cells, for example. So to claim, as was done in 2001, these bone marrow stem cells could turn into heart muscle was both surprising and exciting.

Analysis shows that, at best, the amount of blood pumped during a contraction of one heart chamber rose by 5 per cent after treatment. In a patient where heart efficiency has fallen to 30 per cent of normal, that could be significant but it is relatively meagre, none the less. And it turns out that this level of improvement results whatever the cells injected into the damaged muscle even if they have no prospect of forming cardiomyoctes.

Even the believers in the technique now agree that implanted cells exert a paracrine action, triggering a helpful inflammatory response or secreting chemicals that boost blood vessel formation. But were still waiting for convincing evidence that a patients lost heart muscle cells can be replaced.

Embryonic stem cells offer one route to that goal, though it is difficult to turn them into the right cell type reliably, and there are other risks, such as uncontrolled growths. Another option has come from work by Prof Richard Lee at the Harvard Stem Cell Institute, who has found that some adult stem cells can recruit other stem cells already in the heart to become cardiomyocytes.

Meanwhile, other fields of medicine that have seen more systematic research on stem cells are making real progress in using them for example, to treat Parkinsons, diabetes and macular degeneration. The lesson here is that, ultimately, it takes careful experiments, not belief, to make that huge leap from the laboratory to the hospital.

Roger Highfield is director of external affairs at the Science Museum Group

More here:
Heart disease and stem-cell treatments: caught in a clinical stampede

Public release date: 11-Jun-2012 [ | E-mail | Share ]

Contact: Susan Martonik smartonik@snm.org 703-652-6773 Society of Nuclear Medicine

Miami Beach, Fla.Finding a way to restore hair growth after substantial hair loss is something of an obsession worldwide. Investigators at the Society of Nuclear Medicine's 2012 Annual Meeting presented how stem cell research for the development of new hair follicles can be monitored with an optical imaging technique that uses bioluminescence, the same process that allows fireflies to light up.

There is a host of treatments available for hair loss, including creams and drugs, but these have not shown to be very effective for hair growth. Hair stem cells signal the actual regeneration of hair follicles and natural hair. A molecular imaging technique called bioluminescence is used to display processes at the cellular level. Bioluminescent signal is generated in specific chemical substances called substrates. These signals are easily recognized with very sensitive optical imaging systems that can see what is happening in the smallest placesin this case in hair stem cells.

"Hair regeneration using hair stem cells is a promising therapeutic option emerging for hair loss, and molecular imaging can speed up the development of this therapy," saysByeong-Cheol Ahn, M.D., Ph.D., professor and director of the department of nuclear medicine at Kyungpook National University School of Medicine and Hospital in Daegu, South Korea. "This study is the first study of hair follicle regeneration using an in vivo molecular imaging technique."

The current research involves grafting hair stem cells in animal models to investigate if they can grow and proliferate as normal cells do. The progress of hair stem cell therapy is non-invasivelytracked with bioluminescentreporter genes in specialized substrates. There are several bioluminescent reporter genes originating fromnot only fireflies, but also beetles, glowworms and other bioluminescent organisms. The strategy of using bioluminescent reporter genesis ideal for stem cell research, because bioluminescence works only in living cells.

In this study, researchers used bioluminescence imaging usingfirefly luciferase coupled with D-luciferin to monitor the engraftment of hair follicle stem cellscalled newborn fibroblastsin mice to track their viability and development into hair folliclesover time. Bioluminescence imaging was performed five times over the course of 21 days after transplantation of the stem cells.

Results of the study showed successful bioluminescence imaging forhair regeneration with hair stem cell transplantation, and new hair follicles were apparent on the surface of skin samples under microscope. More studies will have to be conducted before clinical trials could be initiated to verify whether this therapy would work for human hair regeneration.

###

Scientific Paper 74: Jung Eun Kim, Byeong-Cheol Ahn, Ho Won Lee, Mi-hye Hwang, Sang-Woo Lee and Jaetae Lee, Nuclear Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea; Seng Hyun Shin and Young Kwan Sung, Immunology, Kyungpook National University School of Medicine, Daegu, Republic of Korea, "In vivo monitoring of survival and proliferation of hair stem cells in hair follicle regeneration animal model," SNM's 59th Annual Meeting, June 9, 2012, Miami Beach, Fla.

Continued here:
Bioluminescence imaging lights up stem cell therapy for hair growth

COLUMBUS, Ga. --

Every year, thousands of people like Noah Hein are diagnosed with blood cancers such as leukemia. A bone marrow or cord blood transplant can save their lives. The patients who do not have a donor in their family, depend on the National Marrow Donor Program and its Be the Match Registry. At this donor drive in honor of Noah , Jimmy Dawes was the 100th person to walk in and join the registry.

I saw the story and read the story about Noah and it touched my heart personally because my father lost a battle with leukemia when I was 14 so it kind of hit home for me personally, says Dawes.

After filling out the paper work, you simply swab your cheeks. Doctors will be looking for a tissue match, specifically the human leukocyte antigen or HLA. HLAs are proteins, or markers found on most cells in your body.

Roderick Gunn works for the National Marrow Donor Program.

If your tissue type comes up as a match, you would then be asked to submit a blood sample, so we could do confirmatory testing to confirm that you are indeed the best possible match, says Gunn.

Then, after passing a physical exam,the transplant is scheduled. There are two ways to give. Peripheral blood stem cells or PBSC and marrow. Gunn says PBSC is used 80 percent of the time but the doctor chooses the best donation method for the patient. PBSC is similar to giving blood at a blood drive.

And they separate the stem cells from your blood while at the same time returning your blood back to you.

In marrow donation, the donor is anesthetized and a special needle is inserted into pelvic bone, and the marrow withdrawn.

Gunn says the program needs more minorities. He says its harder to match minority patients with donors because the pool is so small. He says often misinformation can keep people away from the program. One myth is its going to cost the donor too much money.

Read more here:
HealthWatch:How to become a marrow donor

Scientists have paved the way for human bones to be replaced with new ones grown outside the body. Photo: iStockphoto

SCIENTISTS have grown human bone from stem cells in a laboratory, paving the way for patients to have broken bones repaired - or even replaced with new ones grown outside the body from their own cells.

Researchers started with stem cells taken from fat tissue. It took about a month to grow them into sections of fully formed living bone up to several centimetres long.

The first trial in patients is on course for later this year, by an Israeli biotechnology company that has been working with academics on the technology.

Advertisement: Story continues below

Professor Avinoam Kadouri, head of the scientific advisory board for Bonus BioGroup, said: ''We use three-dimensional structures to fabricate the bone in the right shape and geometry. We can grow these bones outside the body and then transplant them to the patient.

''By scanning the damaged bone area, the implant should fit perfectly and merge with the surrounding tissue. There are no rejection problems as the cells come from the patient.''

The technology, developed with researchers at the Technion Institute of Research in Israel, uses three-dimensional scans of damaged bone to build a gel-like scaffold that matches the shape.

Stem cells, known as mesenchymal stem cells, that have the capacity to develop into many other types of body cell, are taken from a patient by liposuction and are then grown into living bone inside a ''bioreactor'' - a machine that provides the conditions to encourage the cells to develop into bone.

Animals have already successfully received bone transplants, but in the latest study, the scientists were able to insert almost 2.5 centimetres of laboratory-grown human bone into a rat's leg bone, where it successfully merged with the remaining animal bone.

More here:
Fixing broken bones a growth industry

"We use three dimensional structures to fabricate the bone in the right shape and geometry. We can grow these bones outside the body and then transplant it to the patient at the right time.

"By scanning the damaged bone area, the implant should fit perfectly and merge with the surrounding tissue. There are no problems with rejection as the cells come from the patient's own body."

The technology, which has been developed along with researchers at the Technion Institute of Research in Israel, uses three dimensional scans of the damaged bone to build a gel-like scaffold that matches the shape.

Stem cells, known as mesenchymal stem cells, which have the capacity to develop into many other types of cell in the body, are obtained from the patient's fat using liposuction.

These are then grown into living bone on the scaffold inside a "bioreactor" an automated machine that provides the right conditions to encourage the cells to develop into bone.

Already animals have successfully received bone transplants. The scientists were able to insert almost an inch of laboratory-grown human bone into the middle section of a rat's leg bone, where it successfully merged with the remaining animal bone.

The technique could ultimately allow doctors to replace bones that have been smashed in accidents, fill in defects where bone is missing such as cleft palate, or carry out reconstructive plastic surgery.

Professor Kadouri said work was also under way to grow the soft cartilage at the ends of bones, which is needed if entire bones are to be produced in a laboratory.

Bone grafts currently involve taking bits of bone from elsewhere in the patients body and transplanting them to the area which is damaged to encourage healing.

More than 250,000 bone grafts are performed in the UK each year, including repairs to damaged jaws and the replacement of bone lost in operations to remove tumours.

Read the original here:
Human bones grown from fat in laboratory

by: Steve G. Jones, Ed.S

Obesity is defined as a body mass index (BMI) of 30.0 or greater. BMI is a ratio determined by weight and height. With a large percentage of Americans classified as being obese, research is showing the effects extra weight and obesity have on a person's overall health. Recent studies show that obese people have an increased risk of developing common kidney cancer, kidney stones, and an increased risk of having a stroke.

A study involving 1,640 participants studied the effects of weight on kidney cancer. The average age of patients was 62 and all participants had kidney tumors. The study showed that patients with a BMI of 30 or higher were 48% more likely to develop clear-cell renal cell cancer (RCC). With every 1 point increase in BMI, obese patients increased their odds of getting kidney cancer by 4%.

Out of all the participants, 67% of the obese patients had kidney cancer compared to 57% of non-obese patients. Researchers do not know why there is a link between obesity and kidney cancer. Researchers are looking into a secondary link involving diabetes, hypertension, hormonal changes, and decreased immune function. Read more…

Cardiofy Heart Care Supplement

Source:
http://feeds.feedburner.com/integratedmedicine

Stuff.co.nz

Liquorice loaded with health benefits Stuff.co.nz Scientists at the Max Planck Institute for Molecular Genetics in Berlin, Germany identified a group of natural substances within liquorice root called amorfrutins. Testing on mice, the scientists found that the consumption of amorfrutins reduced blood ... and more »

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

TIME

Paging Doogie Howser: 21-Year-Old Prodigy to Graduate from Medical School TIME He will graduate this week with an MD as well as a Ph.D. in molecular genetics and cell biology. He is the youngest student to receive an MD in the university's history, according to the Chicago Tribune. To say that Yano was an early bloomer is a bit ... Prodigy, 21, becomes youngest MD from Univ. of Chicagomsnbc.com 21-Year-Old Chicago Man Becomes an MDEveryday Health all 8 news articles »

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

New York Daily News

Prodigy gets his MD at age 21; Sho Yano is preparing for his residency in ... New York Daily News Sho Yano, who was reading at age 2, writing at 3 and composing music at 5, will graduate this week from the Pritzker School of Medicine, where he also received a Ph.D. in molecular genetics and cell biology. Yano earned his undergraduate degree from ... Dr. Sho Yano: Chicago med graduate is Asian Doogie Howsernewjerseynewsroom.com Youngest MD: 21-year-old Sho Yano sets world record (PICS & Video)World Records Academy Former child genius graduates from medical school at age 21Los Angeles Times International Business Times all 27 news articles »

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

The West Australian

Child prodigy earns medical degree at age 21 Detroit Free Press Sho Yano, who was reading at age 2, writing at 3 and composing music at 5, will graduate this week from the Pritzker School of Medicine, where he also received a Ph.D. in molecular genetics and cell biology, the Chicago Tribune reports. Child prodigy who licked college by 12 adds MD to his PhDMyFox Philadelphia all 298 news articles »

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

The $3 billion California stem cell
agency, which hopes to generate income for the state through the sale
of stem cell therapies, is moving to make its profit-sharing rules
more friendly to business.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

California biotech companies chalked up
a zero in the latest funding round by the state's $3 billion stem
cell agency, although 14 tried to run a gauntlet that industry has
complained about for years.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss